Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 3/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 17/20 | 0.70 |
| ▸ | GRM3 | Q14832 | 14/20 | 0.70 |
| ▸ | GRM6 | O15303 | 13/20 | 0.70 |
| ▸ | GRM5 | P41594 | 4/20 | 0.70 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.70 |
| ▸ | GRM8 | O00222 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319986 | 1.00 | GRM1 (1.00) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL4692276 | 0.82 | GRM2 (1.00) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL10577620 | 0.77 | GRM1 (0.62) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL25660648 | 0.77 | GRM1 (0.62) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL670022 | 0.77 | GRM1 (0.62) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL5183321 | 0.71 | GRM1 (0.55) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL25182540 | 0.67 | GRM1 (0.50) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL8425584 | 0.67 | GRM2 (0.56) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL8425583 | 0.67 | GRM2 (0.56) | GRM1GRM2GRM3GRM6GRM5 | |
| SCHEMBL25179099 | 0.63 | GRM1 (0.46) | GRM1GRM2GRM3GRM6GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750364-B2 | FOR PROPHYLAXIS AND THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER AND SCHIZOPHRENIFORM DISORDER, COGNITIVE DEFICITS DUE TO AGING, STROKE, ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISEASES | WYETH | 2004-06-15 | — | — | US | disclosed |
| US-6689905-B2 | REACTING 2,6-DIMETHYL-3-OXO-BICYCLO(2.2.1)HEPTANE-1-CARBOXYLIC ACID, SEPARATING THE DIASTEREOMERS USING REVERSED PHASE CHROMATOGRAPHY | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-20030022930-A1 | For prophylaxis and therapy of schizophrenia, schizoaffective disorder and schizophreniform disorder, cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases | WYETH (US) | 2003-01-30 | — | — | US | disclosed |
| US-20030018211-A1 | Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003002513-A1 | STEREOISOMERS OF 3-AMINOTRICYCLO[2.2.1.0(2,6)]HEPTANE-1,3-DICARBOXYLIC ACID | WYETH (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002513-A1 | STEREOISOMERS OF 3-AMINOTRICYCLO[2.2.1.0(2,6)]HEPTANE-1,3-DICARBOXYLIC ACID | WYETH (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002515-A1 | BRIDGED TRICYCLIC ANALOGS OF 2-(CARBOXYCYCLOPROPYL)GLYCINE AS INHIBITORS OF GLUTAMATE TRANSPORT | WYETH (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018211-A1 | Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid | SLC10A1, PKD1, SLC10A2 | GRM1 578/4885GRM2 665/4885GRM3 831/4885 |
| US-20030022930-A1 | For prophylaxis and therapy of schizophrenia, schizoaffective disorder and schizophreniform disorder, cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases | GRIN1, GRIN2C, GRIN2A | GRM1 9/4885GRM2 12/4885GRM3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.